Quantitative assessment of background parenchymal enhancement is associated with lifetime breast cancer risk in screening MRI.
| Autor: | Yan R; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. ranyan@mednet.ucla.edu.; Department of Bioengineering, Henry Samueli School of Engineering, University of California, Los Angeles, CA, USA. ranyan@mednet.ucla.edu., Murakami W; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.; Department of Radiology, Showa University Graduate School of Medicine, Tokyo, Japan., Mortazavi S; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA, USA., Yu T; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA, USA., Chu FI; Department of Radiation Oncology, University of California, Los Angeles, CA, USA., Lee-Felker S; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA, USA., Sung K; Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.; Department of Bioengineering, Henry Samueli School of Engineering, University of California, Los Angeles, CA, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | European radiology [Eur Radiol] 2024 Oct; Vol. 34 (10), pp. 6358-6368. Date of Electronic Publication: 2024 Apr 29. |
| DOI: | 10.1007/s00330-024-10758-9 |
| Abstrakt: | Objectives: To compare the quantitative background parenchymal enhancement (BPE) in women with different lifetime risks and BRCA mutation status of breast cancer using screening MRI. Materials and Methods: This study included screening MRI of 535 women divided into three groups based on lifetime risk: nonhigh-risk women, high-risk women without BRCA mutation, and BRCA1/2 mutation carriers. Six quantitative BPE measurements, including percent enhancement (PE) and signal enhancement ratio (SER), were calculated on DCE-MRI after segmentation of the whole breast and fibroglandular tissue (FGT). The associations between lifetime risk factors and BPE were analyzed via linear regression analysis. We adjusted for risk factors influencing BPE using propensity score matching (PSM) and compared the BPE between different groups. A two-sided Mann-Whitney U-test was used to compare the BPE with a threshold of 0.1 for multiple testing issue-adjusted p values. Results: Age, BMI, menopausal status, and FGT level were significantly correlated with quantitative BPE based on the univariate and multivariable linear regression analyses. After adjusting for age, BMI, menopausal status, hormonal treatment history, and FGT level using PSM, significant differences were observed between high-risk non-BRCA and BRCA groups in PE Conclusion: Quantitative BPE varies in women with different lifetime breast cancer risks and BRCA mutation status. These differences may be due to the influence of multiple lifetime risk factors. Quantitative BPE differences remained between groups with and without BRCA mutations after adjusting for known risk factors associated with BPE. Clinical Relevance Statement: BRCA germline mutations may be associated with quantitative background parenchymal enhancement, excluding the effects of known confounding factors. This finding can provide potential insights into the cancer pathophysiological mechanisms behind lifetime risk models. Key Points: Expanding understanding of breast cancer pathophysiology allows for improved risk stratification and optimized screening protocols. Quantitative BPE is significantly associated with lifetime risk factors and differs between BRCA mutation carriers and noncarriers. This research offers a possible understanding of the physiological mechanisms underlying quantitative BPE and BRCA germline mutations. (© 2024. The Author(s).) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink